SAN DIEGO — A recent clinical trial presented at the American Association for Cancer Research meeting has revealed that all 20 patients treated with CAR-T therapy for smoldering multiple myeloma exhibited no detectable myeloma cells post-treatment. This outcome is particularly significant as it surpasses the typical responses observed in multiple myeloma cases, raising hopes that these patients may have effectively averted the progression to active cancer.
The implications of these findings are profound, especially given the limited treatment options currently available for high-risk smoldering myeloma, with only one approved therapy, Darzalex, which often fails to achieve deep molecular responses. As noted by Ecaterina Dumbrava from MD Anderson Cancer Center, this trial raises critical questions about the potential for early immune intervention not only to delay disease progression but also to redefine treatment objectives. The prospect of discussing a ‘cure’ for this condition, previously considered elusive, may now be on the horizon.
Use the database as your supply chain compass →
